Iron deficiency is a common cause of anemia in chronic kidney disease and can often be corrected with intravenous iron

Journal of Nephrology

Volumn 19, Issue 2, 2006, Pages 161-167

  Gotloib, Lazaro ^a   Silverberg, Donald ^b   Fudin, Roberto ^a   Shostak, Avshalom ^a  

^a HAEMEK MEDICAL CENTER   (Israel)

^b TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

Author keywords

Anemia; Ferric gluconate; Iron; Iron deficiency; Renal failure

Indexed keywords

FERRIC GLUCONATE; FERRITIN; HEMOGLOBIN; IRON; TRANSFERRIN;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTICLE; BONE MARROW BIOPSY; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; DRUG INTERMITTENT THERAPY; ERYTHROCYTE COUNT; FEMALE; FERRITIN BLOOD LEVEL; HEMOGLOBIN DETERMINATION; HUMAN; IRON BLOOD LEVEL; IRON DEFICIENCY; IRON DEFICIENCY ANEMIA; MALE; STERNUM;

AGED; ANEMIA, IRON-DEFICIENCY; BONE MARROW; ERYTHROCYTES; FEMALE; FERRIC COMPOUNDS; FERRITINS; HEMATINICS; HEMOGLOBINS; HUMANS; IRON; KIDNEY DISEASES; MALE; MIDDLE AGED; PROSPECTIVE STUDIES;

EID: 33748861418     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. Gotloib L, Ludicer H, Mines M, Ackerman J. Iron storage in chronic uremic undialysed patients. Dial Transplant 1983; 12: 442B-442E.
2. Shostack A, Meshiaj D, Waiss D, Gotloib L. Intramuscular iron replenishment and replacement combined with testosterone enanthate in maintenance hemodialysis: a follow-up of 8 years on 16 patients. Clin Nephrol 1985; 23: 303-6.
3. Fudin R, Jaichenko J, Shostack A, Bennett M, Gotloib L. Correction of uremic iron deficiency in hemodialyzed patients: a prospective study. Nephron 1998; 79: 299-305.
4. Silverberg DS, Blum M, Peer G, Kaplan E, Iaina A. Intravenous ferric saccharate as an iron supplement in dialysis patients. Nephron 1996; 72: 413-7.
5. Bennett L, Cornes B. Evaluation of a standardized approach to iron supplement for patients who are not hemodialyzed. British Renal Society meeting, Harrogate, 20 May 2004. Abstract.
6. Blaustein DA, Chattopadhyay J, Singh H. The hemoglobin response to rapid, high dose intravenous iron sucrose therapy in anemic chronic kidney disease patients not receiving hematopoietic hormone therapy. J Am Soc Nephrol 2004; 15 (suppl): S549A.
7. Atray N, Simpson S, Maeweathers G. Total dose iron dextran infusion in chronic kidney disease: safety and efficacy. J Am Soc Nephrol 2003; 14 (suppl): S771A.
8. Post JB, Wilkes BM. Iron deficiency in patients with chronic kidney disease: potential role for intravenous iron therapy. J Am Soc Nephrol 2003; 14 (suppl): S792A
9. Anuradha S, Singh NP, Agarwal SK. Total dose infusion iron dextran therapy in predialysis chronic renal failure patients. Ren Fail 2002; 24: 307-13.
10. Silverberg DS, Blum M, Agbaria Z, Deutsch V, Irony M, Schwartz D, Baruch R, Yachnin T, Steinbruch S, Iaina A. The effect of i.v. iron alone or in combination with low dose erythropoietin in the rapid correction of anemia of chronic renal failure in the predialysis period. Clin Nephrol 2001; 55: 212-9.
11. Locatelli F, Aljama P, Barany P, Canaud B, Carrera F, Eckardt KU, Horl WH, Macdougal IC, Macleod A, Wiecek A, Cameron S. Revised European Best Practice Guidelines for the Management of Anaemia in Patients with Chronic Renal Failure. Nephrol Dial Transplant 2004; 19 (suppl 2): S1-47.
12. Besarab A, Amin N, Ahsan M, Vogel SE, Zazuwa G, Frinak S, Zazra JJ, Anandan JV, Gupta A. Optimization of epoetin therapy with intravenous iron therapy in hemodialysis patients. J Am Soc Nephrol 2000; 11: 530-8.
13. DeVita MV, Frumkin D, Mittal S, Kamran A, Fishbane S, Michelis MF. Targeting higher ferritin concentrations with intravenous iron dextran lowers erythropoietin requirement in hemodialysis patients. Clin Nephrol 2003; 60: 335-40.
14. Li S, Foley RN, Gilbertson DT, Liu J, Collins AJ. Clinical factors associated with achieving K/DOQI hemoglobin targets in hemodialysis patients. Int Urol Nephrol 2003; 35: 399-405.
15. Canavese C, Bergamo D, Ciccone G, Burdese M, Maddalena E, Barbieri S, Thea A, Fop F. Low dose continuous iron therapy leads to positive iron balance and decreased serum transferrin levels in chronic hemodialysis patients. Nephrol Dial Transplant 2004; 19: 1564-70.
16. Kooistra MP, Kersting S, Gosriwatand I, Lu S, Nijhoff-Schutte J, Hider RC, Marx JJ. Nontransferrin-bound iron in the plasma of hemodialysis patients after intravenous iron saccharate infusion. Eur J Clin Invest 2002; 32 (suppl 1): S36-41.
17. Hutchinson C, Al-Ashgar W, Liu DY, Hider RC, Powell JJ, Geissler CA. Oral ferrous sulphate leads to a marked increase in pro-oxidant non transferring-bound iron. Eur J Clin Invest 2004; 34: 782-4.
18. Van Wyck DR. Labile iron: manifestations and clinical implications. J Am Soc Nephrol 2004; 15 (suppl 2): S107-11.
19. Folkert VW, Michael B, Agarwall R, Coyne DW, Dahl N, Myirski P, Warnock DG. Chronic use of sodium ferrlecit gluconate complex in hemodialysis patients: safety of a higher dose (> or = 250mg) administration. Am J Kidney Dis 2003; 41: 651-7.
20. Bhowmik D, Modi G, Ray D, Gupta S, Agarwal SK, Tiwari SC, Dash SC. Total dose iron infusion: safety and efficacy in predialysis patients. Ren Fail 2000; 22: 39-43.
21. Jain AK, Bastani B. Safety profile of a high dose ferric gluconate in patients with severe chronic renal insufficiency. J Nephrol 2002; 15: 681-3.
22. Silverberg DS, Iaina A, Peer G, Kaplan E, Levi BA, Frank N, Steinbruch S, Blum M. Intravenous iron supplementation for the treatment of the anemia of moderate to severe chronic renal failure patients not receiving dialysis. Am J Kidney Dis 1996; 27: 234-8.
23. Stenvinkel P. Anemia and inflammation: what are the implications for the nephrologists? Nephrol Dial Transplant 2003; 18 (suppl 8): S17-22.
24. Kalantar-Zadeh K, Stenvinlel P, Pillon L, Kopple JD. Inflammation and nutrition in renal insufficiency. Adv Ren Replace Ther 2003; 10: 155-69.
25. Panesar A, Agarwal R. Safety and efficacy of sodium ferric gluconate complex in patients with chronic kidney disease. Am J Kidney Dis 2002; 40: 924-31.
26. Jenkins K, Andeson C, de Freitas S, Stevens P. Anaemia management in CKD patients not receiving haemodialysis. British Renal Society meeting, Harrogate, 20 May 2004. Abstract.
27. Eschbach JW, Cook JD, Finch CA. Iron absorption in chronic renal disease. Clin Sci 1970; 38: 191-6.
28. Donnelly SM, Posen GA, Ali MA. Oral iron absorption in hemodialysis patients treated with erythropoietin. Clin Invest Med 1991; 14: 271-6.
29. Kooistra MP, Niemantsverdriet EC, van Es A, Mol-Beermann NM, Struyvenberg A, Marx JJ. Iron absorption in erythropoietin-treated haemodialysis patients: effects of iron availability, inflammation and aluminum. Nephrol Dial Transplant 1998; 13; 82-8.
30. Koistra MP, Marx JJ. The absorption of iron is disturbed in recombinant human erythropoietin-treated peritoneal dialysis patients. Nephrol Dial Transplant 1998; 13: 2578-82.
31. Dahdah K, Patrie JT, Bolton WK. Intravenous iron dextran in predialysis patients with chronic renal failure. Am J Kidney Dis 2000; 36: 775-82.
32. Macdougall I, Tucker B, Thompson J, Tomson CR, Baker LR, Raine AE. A randomized controlled study of iron supplementation in patients treated with erythropoietin. Kidney Int 1996; 50: 1694-9.
33. Markowitz GS, Kahn GS, Feingold RE, Coco M, Lynn RI. An evaluation of the effectiveness of oral iron on hemo-dialysis patients receiving recombinant human erythropoietin. Clin Nephrol 1997; 48: 34-40.
34. Fishbane S, Frei GL, Maesaka J. Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation. Am J Kidney Dis 1995; 26: 41-6.
35. Nissenson AR, Lindsay RM, Swan S, Seligman P, Strobos J. Sodium ferric gluconate complex in sucrose is safe and effective in hemodialysis patients: North American Clinical Trial. Am J Kidney Dis 1999; 33: 471-82.
36. Kazmi WH, Kausz AT, Khan S, Abichandani R, Ruthazer R, Obrador GT, Pereira BJ. Anemia: an early complication of chronic renal insufficiency. Am J Kidney Dis 2001; 38: 803-12.
37. Hsu CY, McCullough CE, Curhan GC. Epidemiology of anemia associated with chronic renal insufficiency among adults in the United States: results from the Third National Health and Nutrition Examination Survey. J Am Soc Nephrol 2002; 13: 504-10.
38. Hsu CY, McCullough CE, Curhan GC. Iron status and hemoglobin level in chronic renal failure. J Am Soc Nephrol 2002; 13: 2783-6.
39. Thomas MC, MacIsaac RJ, Tsalamandris C, Power D, Jerums G. Unrecognized anemia in patients with diabetes. Diabetes Care 2003; 26: 1164-9.
40. Astor BC, Muntner P, Levin A, Eustace JA, Coresh J. Association of kidney function with anemia. The Third National Health and Nutrition Examination Survey. (1988-1994). Arch Intern Med 2002; 162: 1401-8.
41. Silverberg DS, Blum M, Agbaria Z, Schwartz D, Zubkov A, Yachnin I, Iaina A. Intravenous iron for the treatment of predialysis anemia. Kidney Int Suppl 1999; 67: S79-85.
42. Silverberg DS, Blum M, Schwartz D. Iron management in predialysis patients. Semin Dial 1999; 12: 262-6.
43. Vaziri ND. Erythropoietin and transferrin metabolism in nephrotic syndrome. Am J Kidney Dis 2001; 38: 1-8.
44. Means RT Jr. Hepcidin and anaemia. Blood Reviews 2004; 18: 219-25.
45. Deicher R, Horl WH. Hepcidin: a molecular link between inflammation and anaemia. Nephrol Dial Transplant 2004; 19: 521-4.
46. Fishbane S, Ungureanu VD, Maesaka JK, Kaupke CJ, Lin V, Wish J. The safety of intravenous iron dextran in hemodialysis patients. Am J Kidney Dis 1996; 28: 529-34.
47. Michael B, Coyne DW, Fishbane S, Folkert V, Lynn R, Nissenson AR, Agarwal R, Eschbach JW, Fadem SZ, Trout JR, Strobos J, Warnock DG. Sodium ferric gluconate complex in hemodialysis patients: adverse reactions compared to placebo and iron dextran. Kidney Int 2002; 61: 1830-9.
48. Chandler G, Harchowal J, Macdougall IC. Intravenous iron sucrose: establishing a safe dose. Am J Kidney Dis 2001; 38: 988-91.
49. Hoen B, Paul-Dauphin M, Hestin D, Krssler M. EPIBACTIAL: a multicenter prospective study of risk factors for bacteremia in chronic hemodialysis patients. J Am Soc Nephrol 1998; 9: 869-76.
50. Leehey DJ, Palubiak DJ, Chebrola S, Agarwal R. Sodium ferric gluconate causes oxidative stress but not acute renal injury in patients with chronic kidney disease: a pilot study. Nephrol Dial Transplant 2005; 20: 135-40.
51. Cavill I. Intravenous iron as adjuvant therapy: a two-edged sword. Nephrol Dial Transplant 2003; 18 (suppl 8): S24-8.
52. Mircescu M, Garneata L, Capusi C, Ursea N. Intravenous iron supplementation for the treatment of anaemia in predialyzed chronic renal failure. Nephrol Dial Transplant 2006; 21: 120-4.
53. Van Wyck DB, Roppolo M, Martinez CO, Mazey RM, McMurray S. A randomized, controlled trial comparing IV sucrose to oral iron in anemic patients with nondialysis dependent CKD. Kidney Int 2005; 68: 2846-56.